212 - Toward a Universal SARS-CoV-2 Vaccine

Saturday, October 22, 2022

10:30 AM – 11:45 AM US ET

Location: 152 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Nadine Rouphael, MD

Professor of Medicine- Director of the Hope Clinic
Division of Infectious Diseases, Department of Medicine
Emory University School of Medicine
Atlanta, Georgia, United States

Disclosure(s): Emmes: Advisor/Consultant (Ongoing); ICON: Advisor/Consultant (Ongoing)
Lisa Jackson, MD, MPH

Senior Investigator
Kaiser Permanente Washington Health Research Institute
Seattle, WA, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Meagan Deming, MD, PHD

Assistant Professor
Center for Vaccine Development, University of Maryland Medical Center
Baltimore, MD, United States

Disclosure(s): No financial relationships to disclose

Slides
Angela Branche, MD

Associate Professor of Medicine
Medicine
University of Rochester
Rochester, New York, United States

Disclosure(s): AzurXBiopharma: Board Member (Terminated); Cyanvac: Grant/Research Support (Ongoing); GSK Vaccines: Advisor/Consultant (Terminated); Janssen Pharmaceutica: Advisor/Consultant (Ongoing); Merck & Co., Inc.: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing)

Slides
Kayvon Modjarrad, MD, PHD

Director, EIDB
Walter Reed Army Institute of Research
Silver Spring, MD, United States

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Nadine Rouphael, MD: Emmes: Advisor/Consultant (Ongoing); ICON: Advisor/Consultant (Ongoing)

Lisa Jackson, MD, MPH: No financial relationships to disclose

Meagan Deming, MD, PHD: No financial relationships to disclose

Angela R. Branche, MD: AzurXBiopharma: Board Member (Terminated); Cyanvac: Grant/Research Support (Ongoing); GSK Vaccines: Advisor/Consultant (Terminated); Janssen Pharmaceutica: Advisor/Consultant (Ongoing); Merck & Co., Inc.: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing)

Kayvon Modjarrad, MD, PHD: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain the use of coronavirus challenge models in the creation of a universal SARS-CoV-2 vaccine;
discuss the current update on the COVAIL trial;
review the timeline and status of the broadly immunogenic nanoparticle vaccine platform

Presentations:

10:30 AM – 10:55 AM US ET

Coronavirus Challenge Models
Speaker: Meagan Deming, MD, PHD – Center for Vaccine Development, University of Maryland Medical Center
10:55 AM – 11:20 AM US ET

Covering the SARS-CoV-2 Antigenic Landscape: The COVAIL Trial and Beyond
Speaker: Angela R. Branche, MD – University of Rochester
11:20 AM – 11:45 AM US ET

From Concept Through Clinical Trial of a Broadly Immunogenic Nanoparticle Vaccine Platform
Speaker: Kayvon Modjarrad, MD, PHD – Walter Reed Army Institute of Research